BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 7682523)

  • 1. Progress toward oligonucleotide therapeutics: pharmacodynamic properties.
    Crooke ST
    FASEB J; 1993 Apr; 7(6):533-9. PubMed ID: 7682523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic applications of oligonucleotides.
    Crooke ST
    Biotechnology (N Y); 1992 Aug; 10(8):882-6. PubMed ID: 1280444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligonucleotide therapy.
    Crooke ST
    Curr Opin Biotechnol; 1992 Dec; 3(6):656-61. PubMed ID: 1369122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Medicinal Chemistry of Therapeutic Oligonucleotides.
    Wan WB; Seth PP
    J Med Chem; 2016 Nov; 59(21):9645-9667. PubMed ID: 27434100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oligonucleotide therapeutics: chemistry, delivery and clinical progress.
    Sharma VK; Watts JK
    Future Med Chem; 2015; 7(16):2221-42. PubMed ID: 26510815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Oligonucleotides: An Outlook on Chemical Strategies to Improve Endosomal Trafficking.
    Mangla P; Vicentini Q; Biscans A
    Cells; 2023 Sep; 12(18):. PubMed ID: 37759475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyamine-oligonucleotide conjugates: a promising direction for nucleic acid tools and therapeutics.
    Menzi M; Lightfoot HL; Hall J
    Future Med Chem; 2015; 7(13):1733-49. PubMed ID: 26424049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The chemistry and biology of oligonucleotide conjugates.
    Juliano RL; Ming X; Nakagawa O
    Acc Chem Res; 2012 Jul; 45(7):1067-76. PubMed ID: 22353142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A status update of modified oligonucleotides for chemotherapeutics applications.
    Sanghvi YS
    Curr Protoc Nucleic Acid Chem; 2011 Sep; Chapter 4():Unit 4.1.1-22. PubMed ID: 21901670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solid-phase synthesis of oligonucleotide conjugates useful for delivery and targeting of potential nucleic acid therapeutics.
    Lönnberg H
    Bioconjug Chem; 2009 Jun; 20(6):1065-94. PubMed ID: 19175328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The delivery of therapeutic oligonucleotides.
    Juliano RL
    Nucleic Acids Res; 2016 Aug; 44(14):6518-48. PubMed ID: 27084936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oligonucleotide technologies: synthesis, production, regulations and applications. 29-30th November 2000, Hamburg, Germany.
    Uhlmann E
    Expert Opin Biol Ther; 2001 Mar; 1(2):319-28. PubMed ID: 11727539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locked nucleic acid: modality, diversity, and drug discovery.
    Hagedorn PH; Persson R; Funder ED; Albæk N; Diemer SL; Hansen DJ; Møller MR; Papargyri N; Christiansen H; Hansen BR; Hansen HF; Jensen MA; Koch T
    Drug Discov Today; 2018 Jan; 23(1):101-114. PubMed ID: 28988994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic RNA-silencing oligonucleotides in metabolic diseases.
    Goga A; Stoffel M
    Nat Rev Drug Discov; 2022 Jun; 21(6):417-439. PubMed ID: 35210608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-molecule oligonucleotides as smart modality for antiviral therapy: a medicinal chemistry perspective.
    Kar SS; Dhar AK; Palei NN; Bhatt S
    Future Med Chem; 2023 Jun; 15(12):1091-1110. PubMed ID: 37584172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Reactive oligonucleotide derivatives as potential antiviral preparations].
    Knorre DG; Vlasov VV
    Vopr Virusol; 1985; 30(5):524-9. PubMed ID: 2416132
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical potential of oligonucleotide-based therapeutics in the respiratory system.
    Moschos SA; Usher L; Lindsay MA
    Pharmacol Ther; 2017 Jan; 169():83-103. PubMed ID: 27771436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of sugar-modified oligonucleotides for antisense therapeutics.
    Prakash TP
    Chem Biodivers; 2011 Sep; 8(9):1616-41. PubMed ID: 21922654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Locked nucleic acids: a promising molecular family for gene-function analysis and antisense drug development.
    Orum H; Wengel J
    Curr Opin Mol Ther; 2001 Jun; 3(3):239-43. PubMed ID: 11497347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.